SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Overview of attention for article published in Clinical Cancer Research, March 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 10 X users

facebook: 1 Facebook page

Readers on

mendeley: 19 Mendeley

So far, Altmetric has seen 14 X posts from 10 X users, with an upper bound of 22,563 followers.

RT @CCR_AACR: Phase 2 Study: Ipilimumab/nivolumab as adjuvant therapy in mucosal melanoma. https://t.co/oz7OYpN5m7 https://t.co/uFQFgfAxn5

Phase 2 Study: Ipilimumab/nivolumab as adjuvant therapy in mucosal melanoma. https://t.co/oz7OYpN5m7 https://t.co/uFQFgfAxn5

RT @TJH0828: @LKottschadeCNP @MayoCancerCare @MayoClinic @CCR_AACR https://t.co/BcQNpXk6r0

RT @CCR_AACR: There is no consensus on adjuvant therapy in muscosal melanoma a rare, aggressive form of #melanoma Kottschade et al report o…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.